A Phase 1 interventional study of Placebo and BI 1015550 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-22.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate safety, tolerability, and pharmacokinetics of multiple rising oral doses of BI 1015550 in healthy male volunteers
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
placebo
Drug: Placebo
powder for oral solution
Drug: BI 1015550
powder for oral solution
Drug: BI1015550
powder for oral solution
Drug: BI 1015550
powder for oral solution
Drug: BI 1015550
Placebo to BI 1015550
medium dose 1 powder for oral solution
medium dose 2 powder for oral solution
low dose 2 powder for oral solution
low dose 1 powder for oral solution
Percentage of Subjects With Drug-related Adverse Events
Percentage of subjects with drug related Adverse events, as assessed by the investigator.
Time frame: From first drug administration until last drug administration, upto 18 days.
Cmax
Maximum measured concentration of BI 1015550 in plasma.
Time frame: 0:15h(hours); 0:30h; 0:45h; 1h;1:15h;1:30h; 2h;3h; 4h; 6h; 8h;10h; 12h; 24h; 34h and 47:55h after first drug administration.
AUCt,1
Area under the concentration-time curve of BI 1015550 in plasma over a uniform dosing interval t after administration of the first dose
Time frame: 0:15h(hours); 0:30h; 0:45h; 1h;1:15h;1:30h; 2h;3h; 4h; 6h; 8h;10h and 12h after first drug administration
AUC0-infinity
Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity.
Time frame: 0:15h(hours); 0:30h; 0:45h; 1h;1:15h;1:30h; 2h;3h; 4h; 6h; 8h;10h; 12h; 24h; 34h and 47:55h after first drug administration.
Cmax,ss
Maximum measured concentration of BI 1015550 in plasma at steady state over a uniform dosing interval t.
Time frame: 311:55h (hours); 312:15h; 312:30h; 312:45; 313h; 313:15h; 313:30h; 314h; 315h; 316h; 318h; 320h; 322h; 324h; 336h; 346h; 360h; 384h & 408h after first drug administration; last drug administration was at 312 h.
AUCt,ss
Area under the concentration-time curve of BI 1015550 in plasma at steady state over a uniform dosing interval t.
Time frame: 311:55h; 312:15h; 312:30h; 312:45; 313h; 313:15h; 313:30h; 314h; 315h; 316h; 318h; 320h; 322h and 324h after first drug administration; last drug administration was at 312 h.
| Milestone | Placebo to BI 1015550 | 1 mg BI 1015550 | 6 mg BI 1015550 |
|---|---|---|---|
| Started | 6 | 9 | 9 |
| Completed | 6 | 8 | 8 |
| Not completed | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Other than stated above | 0 | 1 | 0 |
Percentage of subjects with drug related Adverse events, as assessed by the investigator.
| Percentage of participants | Placebo to BI 1015550 | 1 mg BI 1015550 | 6 mg BI 1015550 |
|---|---|---|---|
| Percentage of Subjects With Drug-related Adverse Events | 16.7 | 44.4 | 11.1 |
Maximum measured concentration of BI 1015550 in plasma.
| nmol/L | 1 mg BI 1015550 | 6 mg BI 1015550 |
|---|---|---|
| Cmax | 24.0 ± 25.1 | 133.0 ± 14.9 |
Area under the concentration-time curve of BI 1015550 in plasma over a uniform dosing interval t after administration of the first dose
| nmol*h/L | 1 mg BI 1015550 | 6 mg BI 1015550 |
|---|---|---|
| AUCt,1 | 94.9 ± 10.3 | 622 ± 20.7 |
Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity.
| nmol*h/L | 1 mg BI 1015550 | 6 mg BI 1015550 |
|---|---|---|
| AUC0-infinity | 131 ± 18.6 | 958 ± 20.9 |
Maximum measured concentration of BI 1015550 in plasma at steady state over a uniform dosing interval t.
| nmol/L | 1 mg BI 1015550 | 6 mg BI 1015550 |
|---|---|---|
| Cmax,ss | 28.6 ± 15.3 | 199 ± 14.5 |
Area under the concentration-time curve of BI 1015550 in plasma at steady state over a uniform dosing interval t.
| nmol*h/L | 1 mg BI 1015550 | 6 mg BI 1015550 |
|---|---|---|
| AUCt,ss | 148 ± 10.7 | 1090 ± 19.6 |
Collected over From first drug administration until last drug administration, upto 18 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo to BI 1015550 | — | 0/6 (0%) | 1/6 (16.7%) |
| 1 mg BI 1015550 | — | 0/9 (0%) | 4/9 (44.4%) |
| 6 mg BI 1015550 | — | 0/9 (0%) | 1/9 (11.1%) |
| Event | Placebo to BI 1015550 | 1 mg BI 1015550 | 6 mg BI 1015550 |
|---|---|---|---|
| HeadacheNervous system disorders | 1/6 | 1/9 | 0/9 |
| Abdominal painGastrointestinal disorders | 0/6 | 1/9 | 1/9 |
| Abdominal pain lowerGastrointestinal disorders | 0/6 | 0/9 | 1/9 |
| Aphthous stomatitisGastrointestinal disorders | 0/6 | 1/9 | 0/9 |
| ConstipationGastrointestinal disorders | 0/6 | 0/9 | 1/9 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 1/9 | 0/9 |
| Oral herpesInfections and infestations | 0/6 | 1/9 | 0/9 |
| ContusionInjury, poisoning and procedural complications | 0/6 | 0/9 | 1/9 |
| Traumatic haematomaInjury, poisoning and procedural complications | 0/6 | 0/9 | 1/9 |
| C-reactive protein increasedInvestigations | 0/6 | 0/9 | 1/9 |
The treated set (TS) included all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.
| Age, Continuous(Years) | Placebo to BI 1015550 | 1 mg BI 1015550 | 6 mg BI 1015550 | Total |
|---|---|---|---|---|
| Mean | 43.5 ± 9.9 | 38.7 ± 8.5 | 44.3 ± 8.3 | 42.0 ± 8.8 |
| Sex: Female, Male(Participants) | Placebo to BI 1015550 | 1 mg BI 1015550 | 6 mg BI 1015550 | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 6 | 9 | 9 | 24 |
The record gives a start of Apr 2013, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nerandomilast